Nelfinavir (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nelfinavir" in Italian language version.

refsWebsite

Global rank Italian rank

15nih.gov

4^th place

9^th place

8oadoi.org

799^th place

22^nd place

8doi.org

2^nd place

7^th place

2ebscohost.com

1,786^th place

3,409^th place

2fda.gov

447^th place

644^th place

1web.archive.org

1^st place

1europa.eu

68^th place

57^th place

doi.org

dx.doi.org

L. Müller, E. Gocke; T. Lavé; T. Pfister, Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 317-29, DOI:10.1016/j.toxlet.2009.04.003, PMID 19443141.
WK. Lutz, The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?, in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 239-42, DOI:10.1016/j.toxlet.2009.07.032, PMID 19695319.
L. Müller, T. Singer, EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 243-7, DOI:10.1016/j.toxlet.2009.02.005, PMID 19857794.
VN. Hirani, JL. Raucy; JM. Lasker, Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19., in Drug Metab Dispos, vol. 32, n. 12, Dic 2004, pp. 1462-7, DOI:10.1124/dmd.104.001743, PMID 15448116.
P. Tebas, WG. Powderly, Nelfinavir mesylate., in Expert Opin Pharmacother, vol. 1, n. 7, Dec 2000, pp. 1429-40, DOI:10.1517/14656566.1.7.1429, PMID 11249476.
M. Olmo, D. Podzamczer, A review of nelfinavir for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 2, Apr 2006, pp. 285-300, DOI:10.1517/17425255.2.2.285, PMID 16866614.
A. Fang, SR. Valluri; MJ. O'Sullivan; R. Maupin; T. Jones; I. Delke; P. Clax, Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum., in HIV Clin Trials, vol. 13, n. 1, pp. 46-59, DOI:10.1310/hct1301-046, PMID 22306587.
S. Baroncelli, E. Tamburrini; M. Ravizza; S. Dalzero; C. Tibaldi; E. Ferrazzi; G. Anzidei; M. Fiscon; S. Alberico; P. Martinelli; G. Placido, Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes., in AIDS Patient Care STDS, vol. 23, n. 7, Jul 2009, pp. 513-20, DOI:10.1089/apc.2008.0263, PMID 19530956.

ebscohost.com

connection.ebscohost.com

Agouron alliance, su connection.ebscohost.com, marzo 1994. URL consultato il 17 ottobre 2012..
Partner gives Agouron $24M; cash flow soars as does stock, su connection.ebscohost.com, settembre 1995. URL consultato il 17 ottobre 2012..

europa.eu

ema.europa.eu

Frederic Bouder, Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders’ expectations and attitudes (PDF), su ema.europa.eu, European Medicines Agency, 15 marzo 2011. URL consultato il 17 ottobre 2012..

fda.gov

FDA, Safety: Viracept (nelfinavir mesylate), su fda.gov, 9 ottobre 2007. URL consultato il 17 ottobre 2012..
Pfizer, Viracept: Important information for prescribers (PDF), su fda.gov, 10 settembre 2007. URL consultato il 17 ottobre 2012..

nih.gov

ncbi.nlm.nih.gov

CM. Perry, P. Benfield, Nelfinavir, in Drugs, vol. 54, n. 1, Lug 1997, pp. 81-7; discussion 88, PMID 9211082.
L. Müller, E. Gocke; T. Lavé; T. Pfister, Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 317-29, DOI:10.1016/j.toxlet.2009.04.003, PMID 19443141.
WK. Lutz, The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?, in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 239-42, DOI:10.1016/j.toxlet.2009.07.032, PMID 19695319.
L. Müller, T. Singer, EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 243-7, DOI:10.1016/j.toxlet.2009.02.005, PMID 19857794.
VN. Hirani, JL. Raucy; JM. Lasker, Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19., in Drug Metab Dispos, vol. 32, n. 12, Dic 2004, pp. 1462-7, DOI:10.1124/dmd.104.001743, PMID 15448116.
Y. Khaliq, K. Gallicano; I. Seguin; K. Fyke; G. Carignan; D. Bulman; A. Badley; DW. Cameron, Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease., in Br J Clin Pharmacol, vol. 50, n. 2, Ago 2000, pp. 108-15, PMID 10930962.
B. Jarvis, D. Faulds, Nelfinavir. A review of its therapeutic efficacy in HIV infection., in Drugs, vol. 56, n. 1, Lug 1998, pp. 147-67, PMID 9664204.
P. Tebas, WG. Powderly, Nelfinavir mesylate., in Expert Opin Pharmacother, vol. 1, n. 7, Dec 2000, pp. 1429-40, DOI:10.1517/14656566.1.7.1429, PMID 11249476.
CM. Perry, JE. Frampton; PL. McCormack; MA. Siddiqui; RS. Cvetković, Nelfinavir: a review of its use in the management of HIV infection., in Drugs, vol. 65, n. 15, 2005, pp. 2209-44, PMID 16225378.
VB. Pai, MC. Nahata, Nelfinavir mesylate: a protease inhibitor., in Ann Pharmacother, vol. 33, n. 3, Mar 1999, pp. 325-39, PMID 10200859.
M. Olmo, D. Podzamczer, A review of nelfinavir for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 2, Apr 2006, pp. 285-300, DOI:10.1517/17425255.2.2.285, PMID 16866614.
A. Fang, SR. Valluri; MJ. O'Sullivan; R. Maupin; T. Jones; I. Delke; P. Clax, Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum., in HIV Clin Trials, vol. 13, n. 1, pp. 46-59, DOI:10.1310/hct1301-046, PMID 22306587.
S. Baroncelli, E. Tamburrini; M. Ravizza; S. Dalzero; C. Tibaldi; E. Ferrazzi; G. Anzidei; M. Fiscon; S. Alberico; P. Martinelli; G. Placido, Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes., in AIDS Patient Care STDS, vol. 23, n. 7, Jul 2009, pp. 513-20, DOI:10.1089/apc.2008.0263, PMID 19530956.
WG. Powderly, P. Tebas, Nelfinavir, a new protease inhibitor: early clinical results., in AIDS, 13 Suppl 1, Set 1999, pp. S41-8, PMID 10546784.
R. Bruno, P. Sacchi; L. Maiocchi; C. Zocchetti; G. Filice, Hepatotoxicity and nelfinavir: a meta-analysis., in Clin Gastroenterol Hepatol, vol. 3, n. 5, Mag 2005, pp. 482-8, PMID 15880318.

oadoi.org

L. Müller, E. Gocke; T. Lavé; T. Pfister, Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 317-29, DOI:10.1016/j.toxlet.2009.04.003, PMID 19443141.
WK. Lutz, The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?, in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 239-42, DOI:10.1016/j.toxlet.2009.07.032, PMID 19695319.
L. Müller, T. Singer, EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view., in Toxicol Lett, vol. 190, n. 3, Nov 2009, pp. 243-7, DOI:10.1016/j.toxlet.2009.02.005, PMID 19857794.
VN. Hirani, JL. Raucy; JM. Lasker, Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19., in Drug Metab Dispos, vol. 32, n. 12, Dic 2004, pp. 1462-7, DOI:10.1124/dmd.104.001743, PMID 15448116.
P. Tebas, WG. Powderly, Nelfinavir mesylate., in Expert Opin Pharmacother, vol. 1, n. 7, Dec 2000, pp. 1429-40, DOI:10.1517/14656566.1.7.1429, PMID 11249476.
M. Olmo, D. Podzamczer, A review of nelfinavir for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 2, Apr 2006, pp. 285-300, DOI:10.1517/17425255.2.2.285, PMID 16866614.
A. Fang, SR. Valluri; MJ. O'Sullivan; R. Maupin; T. Jones; I. Delke; P. Clax, Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum., in HIV Clin Trials, vol. 13, n. 1, pp. 46-59, DOI:10.1310/hct1301-046, PMID 22306587.
S. Baroncelli, E. Tamburrini; M. Ravizza; S. Dalzero; C. Tibaldi; E. Ferrazzi; G. Anzidei; M. Fiscon; S. Alberico; P. Martinelli; G. Placido, Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes., in AIDS Patient Care STDS, vol. 23, n. 7, Jul 2009, pp. 513-20, DOI:10.1089/apc.2008.0263, PMID 19530956.

web.archive.org

The Agouron Institute: history, su agi.org. URL consultato il 17 ottobre 2012. (archiviato dall'url originale il 25 ottobre 2012).